Previous 10 | Next 10 |
BUFFALO, N.Y., June 23, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Daniel Lang, M.D., Presi...
Buffalo, New York-based biotech Athenex (NASDAQ:ATNX) has agreed to sell the revenue generated from the U.S. and European royalty and milestone interests in skin care treatment Klisyri for Sagard Healthcare Partners and Oaktree Capital Management for $85M. Klisyri, also known as tirbanibulin ...
Company executes on strategy to extend cash runway by monetizing non-core assets Total transaction value of $85 million; at least $80 million to be used toward debt paydown and to fund operations BUFFALO, N.Y., June 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ...
BUFFALO, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Darrel ...
Merck (MRK) has struck a collaboration and supply agreement with the cancer-focused biotech, Athenex (NASDAQ:ATNX) to jointly study its anti-PD-1 therapy Keytruda (pembrolizumab) with Athenex’s lead candidate Oraxol in patients with non-small cell lung cancer (NSCLC). Currently, Oraxol...
BUFFALO, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a clinical trial collaborat...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Athenex, Inc. (ATNX) Q1 2022 Earnings Conference Call May 10, 2022, 08:00 AM ET Company Participants Caileigh Dougherty - Investor Relations Johnson Lau - Chief Executive Officer Daniel Lang - President, Athenex Cell Therapy Jeffrey Yordon - Chief Operating Officer Joe Annoni - Chief Financia...
Athenex press release (NASDAQ:ATNX): Q1 GAAP EPS of -$0.16 beats by $0.03. Revenue of $29.7M (-27.6% Y/Y) beats by $4.28M. FY22 Guidance: Athenex now expects product sales growth to be in the range of 20-25% over the prior year period, versus the prior range of 15-20% growth, year-over-year, ...
Reports 1Q product sales of $29.0M, up 42% year-over-year Encouraging interim update from ANCHOR study of KUR-502 presented at ASTCT with 60% overall response rate (ORR) and 6-month complete response (CR) rate of 29% in the NHL cohort Abstract for KUR-501 in GINAKIT2 stu...
News, Short Squeeze, Breakout and More Instantly...
Athenex Inc. Company Name:
ATNX Stock Symbol:
NASDAQ Market:
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (...
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO PR Newswire SAN FRANCISCO , May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and At...
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $1...